Dermata Therapeutics, Inc.
DRMAWDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DMT310 | Phase 3 | Acne Vulgaris | - | - |
Frequently asked questions
What is in Dermata Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Dermata Therapeutics, Inc.'s (DRMAW) pipeline across Phase 3. Its lead program is DMT310 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dermata Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Dermata Therapeutics, Inc. (DRMAW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DRMAW biotech catalysts?→
Add DRMAW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dermata Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.